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Abstract
Background: Genetic alterations in chromatin modulators such as BRCA-1 associated protein-1 (BAP1) are the most
frequent genetic alteration in intrahepatic cholangiocarcinomas (CCA). We evaluated the contribution of BAP1
expression on tumor cell behavior and therapeutic sensitivity to identify rationale therapeutic strategies.
Methods: The impact of BAP1 expression on sensitivity to therapeutic agents was evaluated in CCA cells with a
7-fold difference in BAP1 expression (KMBC-low, HuCCT1-high) and genetically engineered haplo-insufficient BAP1
knockout cells. We also identified long non-coding RNA genes associated with loss of BAP1 and their role in
therapeutic sensitivity.
Results: Sensitivity to gemcitabine was greater in low BAP1 expressing or BAP1 knockout cells compared with the
high BAP1 expressing cells or control haplo-insufficient cells respectively. Similar results were observed with TSA,
olaparib, b-AP15 but not with GSK126. A differential synergistic effect was observed in combinations of gemcitabine
with olaparib or GSK126 in KMBC cells and TSA or bAP15 in HuCCT1 cells, indicating BAP1 dependent target-
specific synergism and sensitivity to gemcitabine. A BAP1 dependent alteration in expression of lncRNA NEAT-1 was
identified by RT-PCR based lncRNA expression profiling, and an inverse relationship between this lncRNA and BAP1
was observed in analysis of the Tumor Cancer Genome Atlas cholangiocarcinoma dataset. Exogenous modulation
of NEAT-1 and/or BAP1 expression altered tumor cell phenotype and modulated sensitivity to gemcitabine.
Conclusions: NEAT-1 is a downstream effector of gemcitabine sensitivity in CCA. The expression of BAP1 is a
determinant of sensitivity to therapeutic drugs that can be exploited to enhance responses through combination
strategies.
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Background
Cholangiocarcinoma (CCA) is a relatively rare malig-
nancy in developed countries with 11,000 estimated new
cases and 3,700 estimated deaths in the United States in
2016 [1]. CCA represents a heterogeneous group of tu-
mors arising from biliary epithelial cells (or cholangio-
cytes) and associated with the intra- or extra-hepatic
biliary tract. The disease has most often progressed to
an advanced stage at the time of clinical presentation
and recurrence rate is high despite surgery. Single-agent
molecular targeted or systemic chemotherapy is the con-
ventional approach for treatment of CCA but is not very
effective. Therapeutic resistance can arise from inter-
individual variation in sensitivity, and specificity of the
target as well as the agent. The use of multimodality ap-
proaches that include combination therapies is a rational
approach to improve therapeutic outcomes if based on
knowledge of cellular mechanisms associated with CCA
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growth and drug response. Recent studies have identified
alterations in chromatin modulators as the most frequent
genetic alterations in intrahepatic cholangiocarcinoma
(iCCA) [2, 3]. Amongst these, mutations in BRCA-1 asso-
ciated protein-1 (BAP1) are the most common, occurring
in 22-24% of cases; however, the clinical impact of muta-
tion or loss of BAP1 in iCCA is yet unknown. The gene is
located on chromosome 3p21 and encodes BAP1, a mem-
ber of the ubiquitin C-terminal hydrolase superfamily of
deubiquitinating enzymes that plays a critical role in chro-
matin remodeling together with ARID1A and PBRM1.
Chromatin remodeling by BAP1 can involve interactions
with several methylation and deacetylase components and
result in modulation of gene expression. We have recently
reported the involvement of long non-coding RNA
(lncRNA) in therapeutic sensitivity in hepatocellular
cancers, but their role in iCCA is unknown [4, 5].
Moreover, the mechanisms by which lncRNA expression
is regulated in cancer cells remain very poorly understood.
Thus, we sought to evaluate the effect of BAP1 on the
modulation of lncRNA involved in therapeutic sensitivity
in iCCA. Our studies identified a novel regulatory niche
between BAP1 and lncRNA nuclear paraspeckle assembly
transcript 1 (NEAT-1) in modulating CCA phenotype and
chemotherapeutic responses to gemcitabine individually
and in combination with target-specific agents such as
EZH2 or PARP inhibitor, GSK126 or olaparib, respect-
ively. Recent evidence suggests a critical role of NEAT-1
in tissue development and as a transcription regulator
promoting oncogenic transcriptome and cell regula-
tory pathways [6–10]. BAP1 and NEAT-1 dictated ex-
clusive drug sensitivity was observed across CCA cell
lines suggesting a key mechanistic role in enhancing
therapeutic effectiveness. These findings provide new in-
sights into the role of tumor suppressor gene - BAP1 in
regulating the expression of NEAT-1, a finding that could
guide rationale combinatorial approaches to enhance
therapeutic sensitivity in iCCA.
Methods
Cell lines, culture, and reagents
Human cholangiocarcinoma cell lines KMBC, HuCCT1,
Mz-ChA-1, CCLP1, human non-malignant intrahepatic
biliary cells H69, and human haploid cells with and
without BAP1 knockout, HAP1 WT and HAP1 BAP1
KO cells (Horizon Genomics, Cambridge, UK) were ob-
tained and cultured as follows: KMBC, HuCCT1, and
CCLP1 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) high-glucose medium (HyClone,
Logan, UT), containing 10% fetal bovine serum (FBS) and
1% antibiotic–antimycotic (Life Technologies, Grand
Island, NY). Mz-ChA-1 cells were cultured in CMRL
1066 media with 10% FBS, 1% L-glutamine and 1%
antibiotic–antimycotic. H69 cells were cultured in
hormonally supplemented DMEM/nutrient mixture F-12
Ham (GIBCO BRL, Gaithersburg, MD) (3:1) containing
adenine, insulin, triiodothyronine-transferrin, hydrocorti-
sone, epinephrine, epidermal growth factor, penicillin/
streptomycin and 10% FBS. Haploid cells were cul-
tured in IMDM media with 10% FBS and 1% antibiotic–
antimycotic. All cell lines were subjected to STR analysis.
Gemcitabine was obtained from Selleckchem (Hous-
ton,TX), cisplatin (Sigma-Aldrich, St. Louis, MO), olaparib
and GSK126 were obtained from Selleckchem (Houston,
TX) and Cayman chemical (Ann Arbor, MI) respect-
ively; trichostatin A (Santa Cruz Biotechnology, Santa
Cruz, CA), and b-AP15 (VLX1500) were provided by
Dr. Asher Chanan-Khan. Compounds were dissolved in
100% cell culture-grade DMSO and diluted with culture
medium to the desired concentration with a final DMSO
concentration of 0.1-0.25%. DMSO 0.1-0.25% (v/v) was
used as a solvent control.
Spheroid cell growth assays
Multicellular tumor spheroids were generated by cultur-
ing cells in the AlgiMatrix 3D cell culture system (Grand
Island, NY). 1 × 106 KMBC cells were seeded in a 6-well
plate in the medium described above using AlgiMatrix
scaffold and 10% firming buffer and allowed to form
spheroids at 37 °C in a 5% CO2 incubator for 7 days.
After a 7 day incubation period, the scaffold was dissolved
using 5 ml dissolving buffer and spheroids were harvested.
For therapeutic response studies, spheroids were seeded
(50 per well) in an ultra-low attachment 96-well plate, and
viable spheroids counted at selected time points using Cell
Titer Glo3D assay (Promega, Madison, WI).
Transient transfections
siRNA against BAP1, NEAT-1 or non-targeting (NT)
control sequences were obtained from Qiagen FlexiTube
siRNA (Valencia, CA) (Additional file 1). Cells were
transfected with either 100 nmol/L siRNA to BAP1 or
75 nmol/L siRNA to NEAT-1 or NT control using
Lipofectamine 2000 (Life Technologies, Grand Island, NY)
in Opti-MEM medium. Two different siRNA to each target
gene were evaluated (sequences in Additional file 1), and
the most efficacious one selected for further study. After
6 h, the medium was replaced with the respective complete
culture medium containing 10% serum and the cells were
incubated for 48 h before further study. BAP1 human
cDNA clone, pCMV6-AC-BAP1 plasmid was purchased
from Origene Technologies, Rockville, MD. KMBC
cells were transfected using Lipofectamine 2000 (Life
Technologies, Grand Island, NY) for 24 h with 2 μg
BAP1 or pcDNA3.1 control vector before further study.
BAP1 CRISPR/Cas 9 knockout plasmid and control
CRISPR/Cas9 plasmid were obtained from Santa Cruz
Biotechnology, Inc (Santa Cruz, CA). The plasmid was
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designed for maximum knockdown efficiency. Using
Lipofectamine 2000 and plasmid transfection medium
H69 cells were transfected with 1 μg of respective
plasmid. After 48 h incubation the transfection effi-
ciency was determined by fluorescent microscopy and
cells were sorted by FACS analysis.
Assessment of therapeutic drug effect on cell growth
Cells were counted using the Vi-CellXR Cell Viability
Analyzer (Beckman Coulter, Brea, CA), seeded at 1 × 103
cells/12 μl/well density in 384-well plate (Corning, NY)
and incubated for at least 12 h prior to drug treatment.
200 μl, 2X of the highest drug concentration per drug was
dispensed in quadruplets in a flat bottom 96-well plate
(Corning, NY) followed by 100 μl of complete medium
dispensed across rest of the plate. A BioTek Precision XS
robot (Winooski, VT) was programmed to prepare serial
dilutions across the plate. Cell viability was assessed after
72 h post-treatment using Cell Titer GloR 2.0 assay
(Promega, Madison, WI) and a BioTek synergy HT- Plate
Reader (Winooski, VT). Data was analyzed using Graph-
Pad Prism to derive the EC50 or IC50 for each drug. For
studies of drug interactions between gemcitabine and
other drugs, cell viability was assessed after incubation
with fixed ratio combinations based on individual drug
IC50 values. Interactions were evaluated using a median
effects analysis to derive a combination index (CI), with a
CI < 1 indicating a synergistic interaction and CI > 1 sug-
gesting an antagonistic effect.
DNA sequencing
Genomic DNA was isolated using a spin-column based
protocol (Qiagen, Valencia, CA). Sequencing primers
for BAP1 gene were designed using GeneRunner
(Additional file 2: Table S1). The extracted DNA was
amplified by PCR using GoTaq Hot Start mix (Promega,
Madison, WI) and purified using Exo-SAP (Affymetrix,
Santa Clara, CA) to remove excess primers and dNTPs as
per the manufacturer’s instructions. 1.6pM of forward or
reverse primers and 5 μl of the purified PCR product
was used for DNA sequencing. Electropherograms ob-
tained were analyzed using SeqScape v2.5 (ABI, Applied
Biosystems, Foster City, CA).
RNA isolation and real-time PCR analysis
Total RNA was extracted from cells using TRIzol (Life
Technologies) and treated with RNase-free DNase I
(Qiagen, Valencia, CA). RNA concentration was measured
using NanoDrop ND-2000 (Nano-Drop Technologies,
Wilmington, DE). One microgram of RNA was reverse-
transcribed to cDNA using iScript cDNA Synthesis Kit
(BIO-RAD Laboratories, Inc., Hercules, CA), and real-time
quantitative RT-PCR was performed using a LightCycler
96 System (Roche Diagnostics, Mannheim, Germany) to
detect BAP1, NEAT-1, NDM29, MER11C, SNHG4, β-
actin, and U6 using SYBR green I (SYBR® Advantage®
qPCR Premix, Clontech, Mountain View, CA). RT-PCR
primer sequences are listed in Additional file 2: Table S2.
PCR based expression profiling of lncRNA was performed
using the LncProfiler qPCR Array Kit (System Biosciences,
Mountain View, CA), according to the manufacturer’s in-
structions. RNA from BAP1 knock-down/out cells were
treated with DNase I and 2 μg of DNase-treated RNA was
reverse transcribed. Real-time PCR was performed (2X
Maxima SYBR Green with Rox) and the cycle number at
which the reaction crossed a threshold (CT) was deter-
mined for each gene. Raw CT values were normalized
using a median CT value (ΔCT =CTlncRNA- CTmedian). For
each lncRNA, the relative amount of each lncRNA be-
tween 2 sample sets A and B was described using the equa-
tion 2-ΔΔCT, where ΔΔCT =ΔCTA -ΔCTB.
Western blot analysis
Protein lysates were obtained from cells grown in
100-mm dishes. Nuclear and cytoplasmic fractions were
obtained using the NE-PER extraction kit (Pierce,
Rockford, IL), Protease Inhibitor Cocktail Tablet and
PhosSTOP Phosphatase inhibitor (Roche, Indianapolis,
IN) according to the manufacturer’s instructions. Protein
concentrations in fractions were determined using the
BCA Protein Assay (Pierce, Rockford, IL). Equivalent
amounts of protein were mixed with 4X LDS sample buf-
fer, incubated for 10 mins at 70 °C and resolved by electro-
phoresis in a 4–12% Bis-Tris gel (Life-Tech) followed by
dry transfer to nitrocellulose membranes using iBlot Dry
Blotting system (Life-Tech). After blocking (Odyssey
Blocking buffer), membranes were incubated with respect-
ive primary antibodies [BAP1 (1:250) or PCNA (1:1000)
(both from Santa Cruz Biotechnology, Santa Cruz, CA) di-
luted in Odyssey blocking buffer solution and incubated at
4 °C overnight, followed by infrared dye-labeled secondary
antibodies (1:10000). The protein of interest was detected
using the LI-COR Odyssey infrared imaging system
(LI-COR Bioscience, Lincoln, NE). Relative expression
was determined by probing against loading control.
Cell cycle analysis
Cells were plated at ~1.25 × 105 cells/well in a 6-well
plate and incubated at 37 °C for 12 h followed by 6 h in-
cubation in serum-free medium. The medium was re-
placed with complete medium containing either IC50
concentration of GSK126 or gemcitabine or a combin-
ation or DMSO control. After 24 h, cells were pelleted
by centrifugation at 300 g for 5 mins, fixed using cold
70% ethanol (KMBC cells) or 4% paraformaldehyde
(HuCCT1 cells) for 15–30 mins and washed twice with
PBS. The cells were re-suspended in PBS and incubated
with 4 mg/ml RNase for 15 mins, and then re-suspended
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in PBS and incubated with 10 mg/ml Propidium Iodide
(PI) for up to 30 mins.100 μl of cell solution was then
transferred to a 96-well plate, analyzed using an Acea
Novocyte flow cytometer, and cell cycle analysis was per-
formed using the integrated software.
Invasion assay
5 × 104 cells were suspended in 200 μl serum-free
medium and loaded onto the upper compartment of
Transwell (Corning, Lowell, MA) 24-well plates with a
pore size of 8.0 μm. Serum-free medium (500 μl) was
added to the bottom. After 24 h, cells that had migrated
through the membrane were fixed and stained using
Diff-Quik (Astral Diagnostics, West Deptford, NJ). Mi-
grated cells were identified and quantitated using a
microscope and average counts from 5 or more fields of
cells were obtained for each group.
Anchorage independent growth assay
Cells transfected with siRNA to NEAT-1 or to respective
nontarget control were seeded in 24-well plate in
complete medium supplemented with 20% serum. Cells
were grown in soft agar as described previously [11].
The final concentration of the bottom and top feeder
layers of the agar system was 1.2% and the cell suspen-
sion layer was 0.8%. Cells were incubated for 7 days in a
humidified incubator at 37 °C. The total number of col-
onies was quantified as a direct proportion of fluorescence.
Alamar Blue (Biosource International, Camarillo, CA) was
added to the wells, and fluorescence was measured using a
BioTek synergy HT- Plate Reader (Winooski, VT) (excita-
tion 530/25 nm; emission 580/50 nm).
Analysis of lncRNA in human CCA
Raw sequences of 36 TCGA CCA RNAseq samples were
obtained from TCGA website [12]. These samples were
analyzed using a Mayo Clinic custom developed bio-
informatics analysis pipeline which aligned the raw se-
quences to GRCh37 using TopHat 2.0 [13], counted the
reads for known mRNAs and lncRNAs defined in
ENSEMBL GTF file using featureCounts [14]. One out-
lier sample was detected by principle component ana-
lysis and removed from further analysis. Genes having
zero read counts in all remaining samples were removed
and the remaining genes were normalized by CQN
method [15]. EdgeR R packages [16] was applied to
compare 10 samples with highest BAP1 gene expression
to 10 samples with lowest BAP1 gene expression, and
differentially expressed genes were identified.
Statistical analysis
Data were expressed as the mean ± standard deviation
from at least three replicates, unless indicated otherwise.
Comparisons between groups were performed using
the two-tailed Student’s t test, one- or two-way ANOVA.
Results were considered to be statistically significant
when P < 0.05.
Results
Basal BAP1 expression in CCA cells
In order to identify an appropriate cellular model, we
began by first performing BAP1 gene mutation analysis
by Sanger sequencing in a panel of human malignant
cholangiocyte cell lines, KMBC, HuCCT1, Mz-ChA-1,
and CCLP1. We identified several BAP1 mutations that
spanned the entire genome (Additional file 2: Table S3).
In KMBC and HuCCT1 cells, only a single point muta-
tion within an intronic region was noted in each line,
neither of which has been observed in iCCA in public
databases such as cBioPortal, or SAGE. Next, we charac-
terized BAP1 RNA and protein expression in all four cell
lines. KMBC cells had the lowest, whereas HuCCT1
cells had the highest BAP1 mRNA expression (Fig. 1a).
Similar results were observed with quantitative immuno-
blot analysis of BAP1 protein expression normalized to
PCNA, with KMBC cells having low BAP1 protein ex-
pression, and HuCCT1 cells having the highest BAP1
protein (Fig. 1b). Based on these analyses, we selected
KMBC cells and HuCCT1 cells as low- and high-BAP1
expressing cells for further analyses. Tumor suppressive
effects resulting from BAP1 mutations likely involve
additional genetic changes such as deletions of chromo-
some 3p. To evaluate the specific effect of loss of BAP1,
we developed a complete BAP1 cellular knock-out
model using HAP1 haploinsufficient cells. HAP1 cells
are near haploid, and have only one set of chromosomes
except for chromosome 8 and 15. A mutated phenotype
is exposed immediately because there is only one copy
of a gene on the haploid chromosomes. The use of these
cells represents a powerful new technique to interrogate
the phenotypic effects of genetic perturbations in human
cancer cells, which is not possible with the use of diploid
cells [17]. To examine the impact of specific loss of
BAP1, BAP1 was knocked out in HAP1 cells using
CRISPR/CAS9 (Additional file 2: Table S4). In these
haplo-insufficient cells (designated as HAP1 BAP1 KO),
there was a complete loss of BAP1 compared with the
parental HAP1 WT cells (Fig. 1c).
BAP1 modulates sensitivity to gemcitabine in CCA cells
We next evaluated the therapeutic sensitivity of CCA
cells with low BAP1 (KMBC) or high BAP1 (HuCCT1)
expression. Gemcitabine and Cisplatin are the current
standard first line systemic agents for the treatment of
CCA. Cells were incubated with varying concentrations
of gemcitabine or cisplatin, for 72 h, and the inhibitory
concentration at 50% effect (IC50) determined. We ob-
served a selective drug response across cell lines (Fig. 2a).
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Sensitivity to gemcitabine was increased in low BAP1 ex-
pressing KMBC cells compared with high BAP1 express-
ing HuCCT1 cells (IC50: 25nM vs 670nM). Similar
trends were observed upon treatment with cisplatin
(IC50: 2 μM vs 12 μM respectively). To further validate
the effect of BAP1 expression on drug sensitivity, we
tested the therapeutic response of these drugs using a hap-
loid cell BAP1 knockout model (Fig. 2b). HAP1 BAP1 KO
cells or their respective control HAP1 WTcells were incu-
bated with therapeutic agents, and concentration-effect
curves analyzed. Sensitivity to gemcitabine was increased
in HAP1 BAP1 KO cells, with an IC50 of 4.5nM
compared with an IC50 of 10.6nM for control HAP1
WT cells. However these cells were insensitive to cis-
platin, and there was no significant difference in sen-
sitivity noted between the HAP1 BAP1 KO (IC50 of
1.4 μM) and HAP1 WT controls (IC50 of 1.4 μM).
Taken together these studies indicate that BAP1 ex-
pression modulates sensitivity to gemcitabine.
Evaluation of candidate therapeutics targeting BAP1-related
drug resistance
We next evaluated whether therapeutic resistance re-
lated to BAP1 expression could be selectively targeted to
improve therapeutic efficacy. To do so, we selected a
panel of candidate compounds with the potential of
modulating BAP1 function. The HDAC inhibitor tri-
chostatin A (TSA) was selected based on the role of
BAP1 in histone ubiquitination, the PARP inhibitor
olaparib (Ola) was used to evaluate BAP1-related sensi-
tivity to PARP inhibition, and b-AP15, an inhibitor of
ubiquitin-specific-processing protease was selected to
test against the deubiquitinating role of BAP1. Sensitivity
to all of these therapeutic agents was increased in low
BAP1 expressing KMBC cells compared with high BAP1
expressing HuCCT1 cells (Fig. 3a): TSA (IC50: 3nM vs
205nM), olaparib (IC50: 2nM vs 68nM), and b-AP15
(IC50: 13nM vs 1.9 μM). In contrast, sensitivity to
GSK126, an inhibitor of enhancer of zeste 2 polycomb
repressive complex 2 (EZH2) was reduced in KMBC
compared with CCLP1 cells (IC50: 49nM vs 3nM).
GSK126 can modulate anti-proliferative results of chro-
matin modification [18]. Similar trends were observed in
haplo-insufficent BAP1 knock-out cells with IC50 values
for HAP1 BAP1 KO cells compared to HAP1 WT cells
as follows: TSA (7nM vs 8nM), Ola (12nM vs 56nM), b-
AP-15 (9nM vs 38nM), GSK126 (42nM vs 8nM) (Fig. 3b).
The R2 coefficient of determination values are provided
in Additional file 2: Table S5. A greater sensitivity to
EZH2 inhibition was noted in cells with higher BAP1
expressing cells (HAP1 WT, HuCCT1) than for low or
absent BAP1 expressing cells (HAP1 BAP1 KO, KMBC).
These results indicated that a, loss of BAP1 expression
could modulate sensitivity to several drugs, and more-
over that EZH2 inhibition could potentially be beneficial
in high BAP1 expressing cells.
Fig. 1 BAP1 protein and mRNA expression in CCA cells. a: BAP1 mRNA expression by quantitative RT-PCR (qRT-PCR). Data represents mean ± SEM
of 2-dCt values normalized to respective β-actin RNA (n = 3). b: Representative western blots and semi-quantitative analysis following normalization
to PCNA of BAP1 protein expression in nuclear (N) or cytosolic (C) fractions under baseline conditions, from three independent studies. c: Western
blot analysis of BAP1 protein expression in parental HAP1 cells (WT) and in HAP1 cells with CRISPR-Cas9 mediated knock-out of BAP-1 (BAP1 KO)
The graph shows the mean ± SEM of 2-dCt values from qRT-PCR expression analysis of BAP1 mRNA normalized to respective β-actin RNA (n = 3).
* P < 0.05. d: BAP1 protein expression in H69 cells by immunocytochemistry and Western blot analysis in nuclear fraction of non-malignant H69
cells. Histone H3 was used as a reference control. BAP1 antibody was purchased from Santa Cruz (SC-28383) and used at a dilution of 1:250
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Evaluation of combination therapies to enhance
sensitivity to gemcitabine
To identify optimal combination strategies for high
BAP1 expressing tumors, we next evaluated the effect of
gemcitabine in combination with other candidate agents.
A combination index was derived for interactions be-
tween gemcitabine and each of TSA, b-AP-15, olaparib
and GSK126. Pharmacologic inhibition of EZH2 using
GSK126 in combination with gemcitabine resulted in a
synergistic reduction in cell viability in low BAP1 ex-
pressing cells, KMBC compared with high BAP1 ex-
pressing, HuCCT1 cells. At a fractional effect of 0.75, a
synergistic effect occurred between gemcitabine and ola-
parib or GSK126 but not with TSA or b-AP-15 in
KMBC cells (Fig. 4a). In marked contrast in HuCCT1
cells, a synergistic effect was not observed with either
olaparib or GSK126, but was noted with TSA and b-AP-
15. Moreover, differential effects on cell cycle progres-
sion were also observed with gemcitabine and GSK126
in KMBC and HuCCT1 cells. In the former, gemcitabine
but not GSK126 arrested cell cycle progression, whereas
in the latter GSK126 neither blocked progression nor
enhanced the effect of gemcitabine (data not shown).
Next, we examined combination treatment with gemci-
tabine and GSK126 using an organotypic culture model
system through the generation of a multicellular 3-
dimensional (3D) KMBC spheroid system. Spheroid
cultures can recapitulate native in vivo scenario and en-
sure an appropriate cell-to-cell contact environment that
is typically presented in vivo. These 3D cultures provide
an alternative to determine drug sensitivity that mitigates
the inter-species differences in cell, microenvironment or
drug metabolism associated with the use of other model
organisms. KMBC cell-derived spheroids were developed
as described in the methods section, with highly consist-
ent size and number. Compared to 2D cell viability assays
using KMBC cells, the IC50 dose for gemcitabine treat-
ment was ~ 20-fold higher in 3D spheroid culture (IC50
25nM vs. 1258nM) (Fig. 4b). Multicellular KMBC spher-
oid cells treated with a combination of gemcitabine and
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Fig. 2 Concentration-dependent cytotoxic effect of gemcitabine or cisplatin. a: KMBC (blue circles) and HuCCT1 (purple squares) cells and b:
haploid BAP1 knockout (HAP1 BAP1 KO) (green circles) or parental haploid HAP1 cells (WT) (orange squares) were plated in 384-well plates (1,000
cells/well), and incubated with varying concentrations of gemcitabine or cisplatin. Cell viability was assessed after 72 h using Cell Titer GloR 2.0
assay. Data represents the average percent cell viability plotted against concentration of drug in nM from 4 replicates for each condition. The
table indicates the inhibitory concentration at 50% effect (IC50) values for each drug for each of the cell lines
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GSK126 had a synergistic effect with a combination index
value of 0.59 compared to CI = 0.78 for KMBC cells in
conventional in vitro studies (Fig. 4c).
BAP1 modulates expression of the lncRNA NEAT-1 in
cholangiocytes
The contribution of lncRNA to therapeutic responses is
becoming recognized. We sought to identify BAP1 regu-
lated candidate lncRNAs that could contribute to thera-
peutic sensitivity. BAP1 was knocked down in H69 non-
malignant cholangiocytes using either siRNA to BAP1 or
using a CRISPR-Cas9 BAP1 construct, and lncRNA
expression was assessed using qRT-PCR based expression
profiling. Suppression of BAP1 expression was confirmed
by western and RT-PCR analysis. We identified several
lncRNAs that were enriched in both siRNA and CRISPR-
Cas9 mediated knock-down of BAP1 compared with the
respective controls (Fig. 5a, Additional file 2: Table S6).
Amongst these were four lncRNAs, NEAT-1, NDM29,
MER11C, and SNHG4 that were at least 5-fold enriched
with BAP1 knock-down with either system. Expression of
these lncRNAs was further validated by qRT-PCR using
independent primer sets, and we confirmed similar trends
in the expression of NEAT-1, NDM29, and MER11C
(Fig. 5b). NEAT-1 has two isoforms. Using qPCR and
primer sets that target both NEAT1_1/NEAT1_2 (Total
NEAT1), or NEAT1_1 alone, we observed an increase in
both total NEAT-1 and NEAT1_1 with siRNA mediated
modulation of BAP1 (Additional file 3). Moreover, the
relative proportion of NEAT1_1 to total NEAT-1 was
unchanged with BAP1 siRNA, suggesting that alteration in
BAP1 equally affects both isoforms. For the rest of our
studies, we studied total NEAT-1. We evaluated data from
the TCGA (Fig. 6a), and observed an inverse correlation
between BAP1 and NEAT-1 expression in iCCA samples
consistent with observations made in the human CCA cell
lines by qRT-PCR (Fig. 6b and c). Next, we evaluated the
contribution of NEAT-1 on cancer cell phenotype. Exogen-
ous modulation of NEAT-1 expression using siRNA against
NEAT-1 (~50% knockdown) in KMBC cells reduced cell
proliferation, migration, invasion and colony-forming abil-
ities relative to non-targeting control siRNA treatment
(Fig. 6d-f). These results indicate that NEAT-1 could con-
tribute to the phenotypic effects associated with CCA.
HuCCT1 KMBC HAP1 WT HAP1 BAP1 KO
Trichostatin A (nM) 205 3 8 7
Olaparib (nM) 68 2 56 12
GSK126 (nM) 3 49 8 42
b-AP-15 (nM) 1974 13 38 9
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Fig. 3 Concentration-dependent cytotoxic effect of candidate therapeutics. a. KMBC (blue circles) and HuCCT1 (purple squares) cells and b:
haploid BAP1 knockout (HAP1 BAP1 KO) (green circles) or parental haploid HAP1 cells (WT) (orange squares) were plated in 384-well plates (1,000
cells/well), and incubated with varying concentrations of the indicated drug. Cell viability was assessed after 72 h using Cell Titer GloR 2.0 assay.
Data represents the average percent cell viability plotted against concentration of drug in nM from 4 replicates for each condition. The table
indicates the inhibitory concentration at 50% effect (IC50) values for each drug for each of the cell lines
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BAP1 and NEAT-1 regulate drug sensitivity in CCA cells
Given the effect of NEAT-1 on modulating the cancer cell
phenotype, we evaluated the potential effect of NEAT-1
on sensitivity to gemcitabine. Modulation of NEAT-1
expression using siRNA in KMBC cells significantly
altered their response to gemcitabine. At an IC50
concentration of 25nM gemcitabine, a significant re-
duction in NEAT-1 siRNA-treated cell proliferation
was observed relative to non-target controls. The im-
pact of BAP1 on sensitivity was further validated in
studies in which KMBC cells were transfected with
BAP1 expression plasmid, and noted to have increased
cytotoxicity to gemcitabine compared with controls trans-
fected with control plasmid transfected cells (Fig. 6g).
Thus, NEAT-1 represents a functional downstream target
of BAP1 involved in drug responses.
Discussion
Alterations in chromatin modulators like the nuclear
deubiquitinating enzyme BAP1 are the most frequently
observed genetic alterations reported in intrahepatic
CCA, yet the molecular mechanisms by which they modu-
late cancer cell behavior are unknown. BAP1 can act as a
tumor suppressor and can regulate several cellular pro-
cesses through its interaction with other protein partners
such as host cell factor 1, O-linked N-acetylglucosamine
transferase, transcription factor Ying Yang1, ASXL1/2,
and FoxK1/K2 and DNA repair proteins like BRCA1/
BARD1 heterodimer and RAD51. In the present
study, we identify alterations in long non-coding RNA
gene expression as a contributor to tumor cell pheno-
type and differential therapeutic sensitivity of CCA
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Fig. 4 Synergistic interactions between candidate agents with gemcitabine. a: Cytotoxicity to drugs was assessed in KMBC (blue circles) and
HuCCT1 (purple squares) cells incubated with gemcitabine (Gem) in combination with trichostatin A (TSA), b-AP15, olaparib, or GSK126 in a fixed
ratio of concentrations, based on the IC50 of each drug. Potential interactions were evaluated using the median effects analysis of Chou and
Talalay, and the combination index (CI) derived, with a CI < 1 indicative of a synergistic and a CI > 1 indicative of an antagonistic effect. At a fractional
effect of 0.75, a synergistic effect was observed between Gem and TSA or b-AP15 in HuCCT1 cells but not with olaparib or GSK126, whereas the
converse was noted in KMBC cells. b: KMBC cells grown in three-dimensional multicellular spheroids and incubated with gemcitabine. Representative
morphological images in spheroid culture (top) and comparison of concentration dependent effects on cell viability cells in conventional in vitro or
spheroid culture (bottom). The IC50 was 25nM in conventional and 1258nM in the spheroid cultures. c: Combination index from median effects
analysis of combination treatment with gemcitabine and GSK126 in KMBC cells cultured under either conventional (conv) or multicellular spheroid
culture. A synergistic effect was observed with cells in spheroid culture, similar to conventional (conv) in vitro culture conditions
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Alterations in BAP1 expression in other cancers such
as renal cell carcinoma, breast carcinoma, small cell and
non-small cell lung cancers, malignant mesothelioma,
metastasizing uveal melanoma, and hepatic cancers can
arise from chromosomal deletions [19, 20]. Germline
BAP1 mutations have been noted in several of these and
other cancers such as meningioma, paraganglioma, basal
cell carcinoma, ovarian cancers, and neuroendocrine
tumors [21, 22]. Genetic mutations in BAP1 could
modulate BAP1 protein expression or could alter BAP1
function in the absence of alterations in protein expres-
sion. Indeed, genetic mutations in BAP1 are variably
associated with loss of protein expression. BAP1 protein
expression has been assessed as a prognostic biomarker
in iCCA. Loss of BAP1 expression by immunohisto-
chemistry was noted in ~26% of a cohort of 211 patients
with iCCA, and was associated with higher histological
grade, absence of lymphatic invasion and a trend to-
wards improved prognosis [3]. The greater sensitivity
to gemcitabine and cisplatin in this setting may re-
flect favorable tumor biology and could contribute to
these observations.
As a chromatin modulator, BAP1 is positioned to epi-
genetically modulate long non-coding RNAs (lncRNAs)
and other genes at the intersection of cellular responses
to an adverse microenvironment such as enhancement
of survival signaling, modulation of cell proliferation and
protein synthesis [23]. Our observations implicate a role
for NEAT-1 as a downstream-target of BAP1 that is in-
volved in responses to therapy as well as in maintenance
of phenotypic characteristics such as the proliferative, mi-
gratory and invasive capabilities of CCA cells. The mecha-
nisms by which NEAT-1 can modulate BAP1 effects are
unknown. A role for NEAT-1 has been described in sev-
eral types of cancers such as breast, prostate, and lung
cancer, with effects on promoting tumor growth through
genetic or epigenetic mechanisms [9, 10]. In pancreatic
cancers, NEAT-1 can promote growth by modulating
levels of miR-335-5p [8]. NEAT-1 can regulate gene ex-
pression through its participation in paraspeckle nuclear
body formation, and further studies to explore how these
effects may be related to modulation of therapeutic re-
sponse are warranted. In addition to NEAT-1, several
other lncRNAs have been implicated as modulators of
drug sensitivity [24]. Examples include reports of lncRNA-
HOTAIR in ER-induced tamoxifen resistance in breast
cancer [25], lncRNA-UCA1 in cisplatin-based resistance
in ovarian cancer cells [26], LncRNA-AK022798 in
cisplatin-based drug resistance in gastric cancer cells [27]
and H19 and lncRNA-ROR in hepatocellular carcinoma
cells [4]. Consistent with the wide diversity of actions of
lncRNA, several different mechanistic pathways have been
Fig. 5 a Long non-coding RNA expression following modulation of BAP1 expression. LncRNA expression by qPCR was compared before and after
experimental manipulation of BAP1 using either siRNA (si-BAP1 KD) or CRISPR/Cas9 in H69 cholangiocytes (c-BAP1-KD). a: Data indicates the
average log2 fold-change (FC) in lncRNA expression in BAP1 knockdown cells from three independent replicates. b Expression of NDM29, NEAT-1,
SNHG4, and MER11C was validated by qRT-PCR using different primer sets. Data represents the mean ± SEM of the ratio of lncRNA to RNU6B
expression relative to controls*, P < 0.05
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implicated in these such as alterations in epithelial-
mesenchymal transition, Wnt signaling, Notch 1, mito-
chondrial apoptosis, cell cycle regulation [28–30]. In an-
other study, lncRNA ENST00000563280 and NR-036444
were found to interact with critical cancer genes such as
ABCB1, HIF1A, and FOXC2 to modulate doxorubicin-
resistance in osteosarcoma patients [31].
The dismal results observed with conventional therap-
ies for CCA such as gemcitabine and cisplatin highlights
the need for more effective drug regimens. Enhanced
sensitivity to PARP inhibition has been reported in
BAP1−/− cells compared with BAP1+/+ and BAP1+/− cells,
as well as in cancer cells harboring inactivating mutations
in BRCA1 or-2 [32, 33]. Our observations of increased
sensitivity to PARP inhibition in the setting of reduced
BAP1 expression are consistent with these reports and
collectively support a role for BAP1 in DNA damage
signaling and repair pathways that could promote the sur-
vival of cells with damaged DNA, drive neoplastic pro-
gression, as well as impact on response to drugs that
induce DNA damage. Reduced BAP1 expression was also





























































































































































Fig. 6 BAP1 and NEAT-1 in CCA. a: Density plot of the distribution of BAP1 expression across 35 iCCA samples from The Cancer Genome Atlas
(TCGA) database, along with b: expression levels of NEAT-1 RNA in patients with low versus high BAP1 expression. c: BAP1 and NEAT-1 mRNA
expression by qRT-PCR in human CCA cell lines. d: Migration and invasion assays were performed in H69 cells as described in the Methods
section. Illustrative bright field microscopic images are shown (left), and number of migrating (middle) or invasive (right) cells/field. e. The
percentage change in viable cell number assessed using Cell Titer GloR 2.0 assay at the indicated times following knockdown of NEAT-1. f.
Anchorage-independent growth of NEAT-1-transfected cells was assessed using a soft agar assay, with fluorometric assessment of colony
formation after 7 days. Bars represent the mean + SEM of 6 separate studies. *, P < 0.05. g, h: BAP1 and NEAT-1 were exogenously modulated in
KMBC cells to determine sensitivity to gemcitabine. KMBC cells were plated in a 6-well culture plate and after 12 h, medium was replaced with
serum-free medium and cells were transfected with (G) NEAT-1 or non-targeting control siRNA for 6 h, or (H) with BAP1 or control plasmid
for 24 h. Cells were then harvested, re-seeded at equal density in a 384-well plate and incubated with 25nM gemcitabine. Cytotoxicity was
determined using Cell Titer GloR 2.0 assay after 72 h. Bars represent the mean + SEM of 4 separate determinants. *, P < 0.05
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enhanced sensitivity to EZH2 inhibition was reported in
mesothelioma cells lacking BAP1 [18], and related to en-
hanced expression of SETD8, a methyl transferase that de-
creased EZH2 expression and further restricted cell
proliferation in these cells. In contrast to observations in
other cancers, sensitivity to pharmacologic inhibition of
EZH2 by GSK126 was decreased in the setting of reduced
BAP1 expression. In CCA patients, EZH2 overexpression
is associated with tumor stage, lymph node positivity, and
poor prognosis [34]. Knockdown of EZH2 is reported to
alter cell cycle regulation and induce G1 arrest leading to
apoptosis in CCA cell lines [35]. We observed an increase
in EZH2 protein and reduced SETD8 with siRNA knock-
down of BAP1 confirming that EZH2 represents a potential
therapeutic target that could be modulated by BAP1. Com-
bination therapy of an EZH2 inhibitor, 3-deazaneplanocin
A, and gemcitabine has had potent synergistic effects
in CCA cells by causing cell cycle arrest and increased
apoptosis [36].
Conclusions
Knowledge of BAP1 expression could guide an appropriate
selection of candidate drugs for combination approaches.
Interestingly, both olaparib and GSK126 had synergistic in-
teractions with gemcitabine in CCA cells, with reduced cell
viability in low-BAP1 KMBC cells in contrast to the effect
observed in high-BAP1 expressing HuCCT1 cells. The ef-
fect of NEAT-1 on modulation of EZH2 expression further
supports an effect of this lncRNA on tumor growth. We
speculate that low BAP1 expressing cells may have a higher
expression of both lncRNA NEAT-1 and EZH2, with a
lower sensitivity to EZH2 inhibition.
Overall, there are limited treatment options for CCA, a
cancer that has been noted to be increasing in incidence
in the US and many other countries. The heterogeneity of
these cancers is being recognized. The evaluation of BAP1
expression, or even EZH2 expression, should be consid-
ered in future therapeutic studies as they may guide
appropriate selection of synergistic combination ap-
proaches that could improve outcomes through improved
therapeutic responses.
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